Posted on

Scientists discover that nicotine promotes spread of lung cancer to the brain

Posted on

Among people who have the most common type of lung cancer, up to 40% develop metastatic brain tumors, with an average survival time of less than six months. But why non-small-cell lung cancer so often spreads to the brain has been poorly understood. Now scientists at Wake Forest School of Medicine have found that nicotine,…

Read more

Posted on

Apalutimide for Prostate Cancer: What to Know

Posted on

The FDA approved apalutamide (Erleada, Janssen Biotech, Inc.) to treat patients with nonmetastatic castration-resistant prostate cancer. Androgen-deprivation therapy (ADT) is an effective and integral part of care for patients with nonmetastatic prostate cancer. However, resistance to ADT is inevitable and develops in almost all cases of prostate cancer. Preventing metastasis to bone and other sites…

Read more

Posted on

Relugolix: Novel Drug for ADT in Advanced Prostate Cancer

Posted on

An investigational new drug for androgen deprivation therapy (ADT) in prostate cancer has shown superiority over the standard therapy leuprolide, and could change practice once it is available, experts have suggested. The new drug is relugolix (Relumina, Myovant Sciences), an oral gonadotropin-releasing hormone (GnRH) antagonist already approved in Japan for use in the treatment of uterine fibroids. Relugolix has the…

Read more

Posted on

New Cancer Drug May treat Malignant Brain Tumor in Kids

Posted on

MTX110, the new formulation of panobinostat, has shown promise in laboratory models of medulloblastoma. It is the focus of a novel trial that places the therapy directly into the fourth ventricle of the brain to treat patients with recurrent medulloblastoma. According to the American Cancer Society, about 500 children are diagnosed with medulloblastoma every year.…

Read more